Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Handok Inc.
• Treatments: Amlodipine; Irbesartan

Criteria

Inclusion Criteria:

• Patients who are 19 years or older on screening

• Signed informed consent

• Patients with Essential Hypertension

• Other inclusion applied

Exclusion Criteria:

• Orthostatic hypotension

• Other exclusion applied